AMAG Pharmaceuticals Appoints Steven Caffe, M.D. as Chief Development and Regulatory Officer

AMAG Pharmaceuticals Appoints Steven Caffe, M.D. as Chief Development and
Regulatory Officer

LEXINGTON, Mass., June 24, 2013 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc.
(Nasdaq:AMAG) today announced the appointment of Steven Caffé, M.D. as senior
vice president and chief development and regulatory officer. Dr. Caffé brings
20 years of experience in global biopharmaceuticals development and regulatory
approvals to AMAG. He joins AMAG from MedImmune, AstraZeneca's global
biologics research and development arm, where he most recently served as
senior vice president of global regulatory affairs and patient safety.

"Steve brings a wealth of relevant development and regulatory experience to
AMAG, gained through a distinguished 20-year career in pharmaceutical
companies ranging from Merck & Co. to MedImmune," said William Heiden,
president and chief executive officer of AMAG. "His experience in global
product development and life-cycle management strategies and execution will be
invaluable to us near-term as we work towards the potential regulatory
approval of Feraheme® for the treatment of iron deficiency anemia in a broader
patient population, and longer-term as our product portfolio expands through
our on-going business development activities. We are pleased to welcome Steve
to AMAG."

Dr. Caffé commented, "AMAG is undergoing a significant turnaround, with the
continued growth of Feraheme and the addition of MuGard™ forming a solid
foundation on which we can build a premier specialty pharmaceutical company. I
am energized to join the company at this time and look forward to sharing the
journey with the talented team at AMAG."

Dr. Caffé has broad-based industry experience across several therapeutic
areas, and in the development of biopharmaceuticals and medical devices. Early
in his career, Dr. Caffé served as a medical director for Parke-Davis, before
its acquisition by Pfizer, and has since had roles of increasing
responsibility at major pharmaceutical companies. Through his experience at
Merck & Co., Sanofi, Baxter and most recently MedImmune, Dr. Caffé has
assembled and led high-performing teams through many development and
regulatory programs, successfully achieving key new product approvals and
extending the life cycle of several commercial products. Dr. Caffé received
his medical degree from the Faculté de Médecine Saint-Antoine, Université
Pierre et Marie Curie (Paris 6), completed his internship and residency, and
practiced medicine at the academic hospitals of the Assistance Publique de
Paris with a focus on emergency and intensive care.

Inducement Equity Awards

In connection with Dr. Caffé's entry into his employment agreement, effective
on the first day of employment, Dr. Caffé will be granted (i) an option to
purchase 60,000 shares of common stock and (ii) 35,000 restricted stock units.
The option will have an exercise price equal to the closing price of AMAG's
common stock on the grant date and will be exercisable in four equal annual
installments beginning on the first anniversary of the grant date. The option
will have a ten-year term and be subject to the terms and conditions of the
stock option agreement pursuant to which the option will be granted. The
restricted stock units will vest in four equal annual installments beginning
on the first anniversary of the grant date and will be subject to the
restricted stock unit agreement pursuant to which the restricted stock units
will be granted.

These equity awards will be granted without stockholder approval as
inducements material to Dr. Caffé's entering into employment with AMAG in
accordance with NASDAQ Listing Rule 5635(c)(4).

About AMAG

AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company that markets
Feraheme® (ferumoxytol) Injection and MuGard™ Mucoadhesive Oral Wound Rinse in
the United States. Along with driving organic growth of its products, AMAG
intends to expand its portfolio with additional commercial-stage specialty
products. The company is seeking complementary products that leverage the
company's commercial footprint and focus on hematology and oncology centers
and hospital infusion centers. For additional company information, please

Forward-looking Statements

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 and other federal
securities laws. Any statements contained herein which do not describe
historical facts, including but not limited to statements regarding: the
approval of the supplemental new drug application Feraheme for a broader
patient population; Dr. Caffé's contributions to AMAG and the intended
expansion and focus of AMAG's product portfolio; the company's intent to drive
organic growth of Feraheme; and the company's plans to seek complementary
commercial products to add to its portfolio are forward-looking statements
which involve risks and uncertainties that could cause actual results to
differ materially from those discussed in such forward-looking statements.

Such risks and uncertainties include: (1) uncertainties regarding our and
Takeda's ability to successfully compete in the intravenous iron replacement
market both in the US and outside the US, including the EU, (2) uncertainties
regarding our ability to compete in the oral mucositis market in the US, (3)
uncertainties regarding our ability to successfully and timely complete our
clinical development programs and obtain regulatory approval
forFeraheme/Riensoin the broader IDA indication both in the US and outside
of the US, including theEU, (4) the possibility that significant safety or
drug interaction problems could arise with respect toFeraheme/Rienso, (5)
uncertainties regarding the manufacture of Feraheme/Rienso or Mugard, (6)
uncertainties relating to our patents and proprietary rights both in the US
and outside the US, (7) the risk of an Abbreviated New Drug Application (ANDA)
filing following the FDA's recently published draft bioequivalence
recommendation for ferumoxytol, and (8) other risks identified in
ourSecurities and Exchange Commission (SEC)filings, including our Quarterly
Report on Form 10-Q for the year endedMarch 31, 2013 and subsequent filings
with the SEC. We caution you not to place undue reliance on any
forward-looking statements, which speak only as of the date they are made.

We disclaim any obligation to publicly update or revise any such statements to
reflect any change in expectations or in events, conditions or circumstances
on which any such statements may be based, or that may affect the likelihood
that actual results will differ from those set forth in the forward-looking

AMAG Pharmaceuticals and Feraheme are registered trademarks of AMAG
Pharmaceuticals, Inc.

Rienso is a registered trademark of Takeda Pharmaceutical Company Limited.
MuGard is a trademark ofAccess Pharmaceuticals, Inc.

CONTACT: AMAG Pharmaceuticals, Inc.
         Amy Sullivan, 617-498-3303
Press spacebar to pause and continue. Press esc to stop.